These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Is Inverse Prism Therapy Comparable to Conventional Prism Therapy for Improving Newcastle Scores in Patients with Basic Intermittent Exotropia?
    Author: Samy El Gendy NM, Abdel Nabi E.
    Journal: Semin Ophthalmol; 2019; 34(7-8):497-503. PubMed ID: 31402742.
    Abstract:
    Purpose: To determine the effect of prism orientation on the Newcastle Control Score (NCS) in patients with basic intermittent exotropia (IXT).Methods: Patients with IXT with a distant angle of deviation (DAD) ≤50∆ and NCS≥5 were recruited and randomly divided into two groups. The inverse prism (IP) group received a base-out Fresnel prism addition to achieving full refractive correction, and the conventional prism (CP) group received base-in Fresnel prism addition. The prism addition was equivalent to one-third of the mean DAD. Patients were evaluated 3 months after initial treatment, 3 months after partial weaning and 6 months after complete weaning. NCS and DAD values were compared. Tolerance was defined as the ability to wear the prescription 80% of waking hours.Results: Fifty patients were enrolled in each group. The IP group had 6 intolerant patients, and the CP group had 3 intolerant patients. NCS improved in both groups (from 6.2 ± 0.7 to 3.4 ± 2.5 in the IP group and from 6.4 ± 0.7 to 3.7 ± -2.2 in the CP group). However, the final NCS difference was nonsignificant (Mann-Whitney, p = .6). The DAD changes were not significantly different between the 2 groups (t-test = 0.04). The average DAD decreased from 31.9 ± 6.9∆ to 10.11 ± 11∆ in the IP group and from 30.7 ± 8.5∆ to 15.5 ± 13.5∆ in the CP group. Four patients in the CP group exhibited an increase in DAD.Conclusion: The two types of prism therapy showed comparable improvements in NCS.
    [Abstract] [Full Text] [Related] [New Search]